Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ

Guan, Xin; Xu, Guiying; Shi, Aiping; Zou, Yabin; Zhan, Yue; Fan, Zhimin; Dong, Yi

doi:10.1097/md.0000000000023487

Cited by 11 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher locoregional recurrence rates of IMPC patients compared to IDC patients. Chen et al (2013) 47 Case Series Study – Distant metastasis in 4.1% of the IMPC patients 5-year DS survival was at 91.9% and OS at 83.8% – Kaya et al (2018) 48 Case Series Study Locoregional recurrence in 15.8% of the patients Distant metastasis in 5.3% of the patients 95.7% of the patients with an average of 48.87 months of follow-up No difference in recurrence rates or survival, between patients with low or high percentage of micropapillary pattern Kim et al (2020) 58 Case–Control Study – – – No difference in overall survival between IMPC and NST patients, in multivariate analysis Guan et al (2020) 101 Case–Control Study Locoregional recurrence in 3.1% of the patients Distant metastasis in 20% of the patients HR for OS for patients with IMPC component was 1.677 when compared to IDC patients Locoregional recurrence was lower for IMPC patients compared to IDC patients. OS was better for IMPC patients.…”

Section: Lymphovascular Invasion and Lymph Node Involvementmentioning

confidence: 99%

See 1 more Smart Citation

Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis

GI¹,

Tchabashvili²,

Mulita³

et al. 2022

BCTT

View full text Add to dashboard Cite

Invasive micropapillary carcinoma (IMPC) of the breast is an infrequent type of breast cancer often discussed for its potency for lymphovascular invasion and difficulty in accurate imaging estimation. Micropapillary carcinomas are noted to be present as larger tumors, of higher histological grade and a notably higher percentage of disease-positive lymph nodes. Hormonal and HER-2 positivity in IMPC is also commoner when compared to other NST carcinomas. IMPC occurs either as a pure form or more often as a component of mixed Non-Specific Type (NST) carcinoma. The latest data suggest that despite having comparable survival rates to other histological subtypes of breast carcinoma, effective surgical treatment often requires extended surgical margins and vigilant preoperative axillary staging due to an increased incidence of lymph node invasion, and locoregional recurrence. Moreover, the presence of micropapillary in situ components within tumors also seems to alter tumor aggression and influence the nodal disease stage. In this review, we present an overview of the current literature of micropapillary carcinoma of the breast from biology to prognosis, focusing on biological differences and treatment.

show abstract

Section: Lymphovascular Invasion and Lymph Node Involvementmentioning

confidence: 99%

“…Higher incidence of vascular invasion, increased stage at diagnosis, high recurrence rates and increased lymph node infiltration are all well documented. 101 …”

Section: Lymphovascular Invasion and Lymph Node Involvementmentioning

confidence: 99%

Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis

GI¹,

Tchabashvili²,

Mulita³

et al. 2022

BCTT

View full text Add to dashboard Cite

show abstract

“…Currently, the presence of micropapillary features within invasive ductal carcinoma (IDC) does not influence the prognosis or guide decisions regarding adjuvant treatment strategies. Comprehensive clinical observations are necessary to uncover the underlying mechanism and formulate personalized treatment approaches [ 52 ]. A summary of all the articles included in the review is listed in Table 3 .…”

Section: Reviewmentioning

confidence: 99%

The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review

Wankhade,

Gharde,

Dutta

2023

Cureus

View full text Add to dashboard Cite

Currently, the prevailing approach for managing breast carcinoma involves initiating neoadjuvant chemotherapy (NAC) as a part of the treatment regimen before surgery. NAC is being applied progressively in the therapeutic management of locally advanced breast carcinoma because of its capability to aid in surgery and facilitate the surgical treatment of patients who were once thought to be inoperable. Patients must be managed by a team of professionals from the start to the completion of the therapy. Pathological complete response (pCR), reduces the degree of recurrence of the disease and denotes the elimination of the tumor completely from the breast, it also indicates elimination of the tumor from the axillary lymph nodes. There is currently sufficient information to support the idea that patients would perform better if NAC resulted in a pCR. The administration of the same regimen of adjuvant therapy in neoadjuvant therapy provides women with similar improvements in overall survival. NAC offers potential benefits, such as enhancing the likelihood of breast conservation and broadening the scope of available surgical options. Based on how well they respond to neoadjuvant treatment, women receive a personalized prognosis evaluation. NAC has been proven to be very effective. However, patients can be resistant to medications easily which is not desirable for patients receiving this therapy going forward. In this review, we have discussed the purpose of managing patients with this therapy in locally advanced breast cancer. We have also discussed the various benefits of NAC as well as the application of different drugs, their advantages, and disadvantages that are given to the patient. The application of NAC in cases of human epidermal growth factor 2 (HER2) positive breast cancer and micropapillary breast cancer has also been discussed briefly in this review.

show abstract

“…IMPC is likely spreading via lymphatic vessels and lymph node metastasis than other subtypes. Guan et al found that IMPC is more aggressive and has inferior diseasefree survival and overall survival (OS) respect to invasive ductal carcinoma and ductal carcinoma in situ 14 . However, recent studies similar long-term survival outcomes 15,16 .…”

Section: Introductionmentioning

confidence: 99%

Authentication of a survival nomogram for non-invasive micropapillary breast cancer

Zhang

Qin

Hou

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose We aimed at establishing a nomogram to accurately forecast the overall survival (OS) of non-metastatic invasive micropapillary breast carcinoma (IMPC). Methods In the training cohort, data from 429 patients with non-metastatic IMPC were obtained through the Surveillance, Epidemiology, and End Results (SEER) database. Other 102 patients were enrolled at the Xijing Hospital as validation cohort. Independent risk factors affecting OS were ascertained using univariate and multivariate Cox regression. A nomogram was established to forecast OS at 3, 5 and 8 years. The concordance index (C-index), the area under a receiver operating characteristic (ROC) curve and calibration curves were utilized to assess calibration, discrimination and predictive accuracy. Finally, the nomogram was utilized to stratify the risk. The OS between groups was compared through Kaplan-Meier survival curves. Results The multivariate analyses revealed that race (p = 0.047), surgery (p = 0.003), positive lymph nodes (p = 0.027), T stage (p = 0.045) and estrogen receptors (p = 0.019) were independent prognostic risk factors. The C-index was 0.766 (95% CI, 0.682–0.850) in the training cohort and 0.694 (95% CI, 0.527–0.861) in the validation cohort. Furthermore, the predicted OS was consistent with actual observation. The AUCs for OS at 3, 5 and and 8 years were 0.786 (95% CI: 0.656–0.916), 0.791 (95% CI: 0.669–0.912), and 0.774 (95% CI: 0.688–0.860) in the training cohort, respectively. The area under the curves (AUCs) for OS at 3, 5 and 8 years were 0.653 (95% CI: 0.498–0.808), 0.683 (95% CI: 0.546–0.820), and 0.716 (95% CI: 0.595–0.836) in the validation cohort, respectively. The Kaplan-Meier survival curves revealed a significant different OS between groups in both cohorts (p༜0.001). Conclusion Our novel prognostic nomogram for non-metastatic IMPC patients achieved a good level of accuracy in both cohorts and could be used to optimize the treatment based on the individual risk factors.

show abstract

Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ

Cited by 11 publications

References 42 publications

Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis

Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis

The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review

Authentication of a survival nomogram for non-invasive micropapillary breast cancer

Contact Info

Product

Resources

About